{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"46","upperLimit":"121","value":"67"},{"groupId":"OG001","lowerLimit":"53","upperLimit":"113","value":"79"},{"groupId":"OG002","lowerLimit":"41","upperLimit":"240","value":"83"},{"groupId":"OG003","lowerLimit":"134","upperLimit":"265","value":"169"},{"groupId":"OG004","lowerLimit":"81","upperLimit":"123","value":"100"},{"groupId":"OG005","lowerLimit":"43","upperLimit":"165","value":"95"},{"groupId":"OG006","lowerLimit":"83","upperLimit":"215","value":"110"},{"groupId":"OG007","lowerLimit":"74","upperLimit":"240","value":"129"},{"groupId":"OG008","lowerLimit":"66","upperLimit":"184","value":"120"},{"groupId":"OG009","lowerLimit":"44","upperLimit":"134","value":"106"},{"groupId":"OG010","lowerLimit":"73","upperLimit":"187","value":"142"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"8"},{"groupId":"OG007","value":"7"},{"groupId":"OG008","value":"9"},{"groupId":"OG009","value":"11"},{"groupId":"OG010","value":"11"}],"units":"Participants"}],"description":"Terminal half-life is defined as the time it takes for the blood plasma concentration of a substance to halve (plasma half-life). Blood samples for measurement of serum levels of dalotuzumab were obtained at: pre-dose; pre-end infusion; 0.5, 5, 10, 24, 30 (Q1W only), 48, 96, 168 (Q2W/Q3W only), 336 (Q3W only) hours post infusion. For infusions \\>1 hour in duration, an additional sample was obtained at the mid-point of the infusion. Data presented are for the harmonic mean t1/2 for dalotuzumab.","dispersionType":"Full Range","groups":[{"description":"Participants received dalotuzumab 1.25 mg/kg (10 mg/mL) IV infusion Q1W.","id":"OG000","title":"Dalotuzumab 1.25 mg/kg Q1W (10 mg/mL)"},{"description":"Participants received dalotuzumab 2.5 mg/kg (10 mg/mL) IV infusion Q1W.","id":"OG001","title":"Dalotuzumab 2.5 mg/kg Q1W (10 mg/mL)"},{"description":"Participants received dalotuzumab 5 mg/kg (10 mg/mL) IV infusion Q1W.","id":"OG002","title":"Dalotuzumab 5 mg/kg Q1W (10 mg/mL)"},{"description":"Participants received dalotuzumab 10 mg/kg (10 mg/mL) IV infusion Q1W.","id":"OG003","title":"Dalotuzumab 10 mg/kg Q1W (10 mg/mL)"},{"description":"Participants received dalotuzumab 10 mg/kg (20 mg/mL) IV infusion Q1W.","id":"OG004","title":"Dalotuzumab 10 mg/kg Q1W (20 mg/mL)"},{"description":"Participants received dalotuzumab 15 mg/kg (10 mg/mL) IV infusion Q1W.","id":"OG005","title":"Dalotuzumab 15 mg/kg Q1W (10 mg/mL)"},{"description":"Participants received dalotuzumab 15 mg/kg (20 mg/ mL) IV infusion Q1W.","id":"OG006","title":"Dalotuzumab 15 mg/kg Q1W (20 mg/mL)"},{"description":"Participants received dalotuzumab 20 mg/kg (10 mg/mL) IV infusion Q1W.","id":"OG007","title":"Dalotuzumab 20 mg/kg Q1W (10 mg/mL)"},{"description":"Participants received dalotuzumab 20.0 mg/kg (20 mg/mL) IV infusion Q1W.","id":"OG008","title":"Dalotuzumab 20 mg/kg Q1W (20 mg/mL)"},{"description":"Participants received dalotuzumab 20 mg/kg (20 mg/mL) IV infusion Q2W.","id":"OG009","title":"Dalotuzumab 20 mg/kg Q2W (20 mg/mL)"},{"description":"Participants received dalotuzumab 30 mg/kg (20 mg/mL) IV infusion Q3W.","id":"OG010","title":"Dalotuzumab 30 mg/kg Q3W (20 mg/mL)"}],"paramType":"MEAN","populationDescription":"The population consisted of all evaluable participants who received \\>90% of intended drug volume and had t1/2 pharmacokinetic measurements at Baseline and at least once during treatment.","reportingStatus":"POSTED","timeFrame":"Predose; pre-end infusion; 0.5, 5, 10, 24, 30 (Q1W only), 48, 96, 168 (Q2W/Q3W only), 336 (Q3W only) hours post-infusion","title":"Mean Terminal Half-life (t1/2) of Dalotuzumab","type":"PRIMARY","unitOfMeasure":"Hours"}